Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- HOOK
- Price
- 1.00
- Stock movement up
- +0.04 (3.96%)
- Company name
- Hookipa Pharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 9.91M
- Ent value
- -295.09K
- Price/Sales
- 0.67
- Price/Book
- 0.35
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -32.13%
- 1 year return (CAGR)
- -51.07%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
HOOK does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.67 |
| Price to Book | 0.35 |
| EV to Sales | -0.02 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 9.93M |
| EPS (TTM) | -4.42 |
| FCF per share (TTM) | -3.59 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 14.86M |
| Gross profit (TTM) | 14.86M |
| Operating income (TTM) | -64.65M |
| Net income (TTM) | -56.00M |
| EPS (TTM) | -4.42 |
| EPS (1y forward) | -1.56 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -435.16% |
| Profit margin (TTM) | -376.98% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 34.23M |
| Net receivables | 9.50M |
| Total current assets | 51.67M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.97M |
| Total assets | 52.71M |
| Accounts payable | 7.60M |
| Short/Current long term debt | 546.00K |
| Total current liabilities | 13.16M |
| Total liabilities | 24.02M |
| Shareholder's equity | 28.68M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -45.53M |
| Capital expenditures (TTM) | 53.00K |
| Free cash flow (TTM) | -45.58M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -195.24% |
| Return on Assets | -106.26% |
| Return on Invested Capital | -193.57% |
| Cash Return on Invested Capital | -157.54% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.99 |
| Daily high | 1.00 |
| Daily low | 0.96 |
| Daily Volume | 3K |
| All-time high | 195.10 |
| 1y analyst estimate | 2.00 |
| Beta | 0.90 |
| EPS (TTM) | -4.42 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| HOOK | S&P500 | |
| Current price drop from All-time high | -99.49% | -0.89% |
| Highest price drop | -99.62% | -19.00% |
| Date of highest drop | 10 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -99.24% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
9.91M
Marketcap category
Small-cap
Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Employees
82
Investor relations
-
SEC filings
CEO
Jörn Aldag
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page